Merck the US pharmaceutical manufacturer has announced a further 8500 job cuts in order to reduce annual operating costs by $2.5bn over the next two years. Merck intends to focus its research on a narrower range of treatment areas; oncology, diabetes, acute hospital care and vaccines, areas with the “highest potential growth”.
